Pancreatic Cancer Research

ResearcherNational Institutes of HealthActive in the last 2 years

Eric Tran

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9070-0980; OpenAlex author ID A5101951123. Sources: OpenAlex.

Their work

Papers
6 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
26
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 6

  1. T cell receptor gene therapy targeting KRAS G12V for advanced pancreatic cancer in a single-arm phase 1/2 clinical trial. Co-author DOI 10.1016/j.ymthe.2026.03.012↗
  2. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. Co-author DOI 10.1172/jci.insight.181873↗
  3. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. Reply. Co-author DOI 10.1056/nejmc2208623↗
  4. Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. Last author DOI 10.1056/nejmoa2119662↗
  5. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. Co-author DOI 10.1080/2162402x.2021.1900635↗
  6. A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Co-author DOI 10.1089/hum.2013.209↗

Closest collaborators

The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rom S. Leidner · 2 shared papers, 2022 · strength 0.39
  2. Suizhi Gao · 2 shared papers, 2025–2026 · strength 0.39
  3. Kailian Zheng · 2 shared papers, 2025–2026 · strength 0.39
  4. Xiongfei Xu · 2 shared papers, 2025–2026 · strength 0.39
  5. Shiwei Guo · 2 shared papers, 2025–2026 · strength 0.39
  6. Xiaoyi Yin · 2 shared papers, 2025–2026 · strength 0.39
  7. Gang Jin · 2 shared papers, 2025–2026 · strength 0.39
  8. Meilong Shi · 1 shared paper, 2026 · strength 0.20
  9. Lingyu Zhu · 1 shared paper, 2025 · strength 0.19
  10. Yunguang Li · 1 shared paper, 2025 · strength 0.19
  11. Bo Li · 1 shared paper, 2025 · strength 0.19
  12. Xiaohan Shi · 1 shared paper, 2025 · strength 0.19
  13. Dong Gao · 1 shared paper, 2025 · strength 0.19
  14. Michael James Gough · 1 shared paper, 2021 · strength 0.10
  15. Marka R. Crittenden · 1 shared paper, 2021 · strength 0.10
  16. Terry R. Medler · 1 shared paper, 2021 · strength 0.10
  17. Paul Hansen · 1 shared paper, 2021 · strength 0.10
  18. Ephraim Shin-Tian Tang · 1 shared paper, 2021 · strength 0.10
  19. Kristina Hoot Young · 1 shared paper, 2021 · strength 0.10
  20. Brady M. Bernard · 1 shared paper, 2021 · strength 0.10
  21. Andrew J. Gunderson · 1 shared paper, 2021 · strength 0.10
  22. Daniel Abate‐Daga · 1 shared paper, 2014 · strength 0.04
  23. Yaroslav Teper · 1 shared paper, 2014 · strength 0.04
  24. William R. Burns · 1 shared paper, 2014 · strength 0.04
  25. Richard A. Morgan · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.